Novo Nordisk Adds Momentum To Oral Semaglutide With Good PIONEER 5 Data

21 Aug 2018

• By Sten Stovall

Novo Nordisk announced another set of positive PIONEER trial data backing its oral GLP-1 receptor agonist semaglutide, this time showing superior reduction of blood sugar levels and weight in adults with type 2 diabetes compared with placebo.

Tablet — PIONEER 5 Used Two statistical approaches evaluating oral semaglutide • Source: Shutterstock

Novo Nordisk Adds Momentum To Oral Semaglutide With Good PIONEER 5 Data

More from Clinical Trials

More from R&D